Results 41 to 50 of about 38,942 (318)

Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts

Biomolecules, 2019
The anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to vascular endothelial growth factor (VEGF), ranibizumab works by binding and neutralizing all active VEGF-A, thus limiting progressive cell growth and proliferation.
Siti Munirah Md Noh, Siti Hamimah Sheikh Abdul Kadir, Sushil Vasudevan   +2 more
doaj   +1 more source

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema

Journal of Ophthalmology, 2018
Purpose. To compare the visual and anatomic outcomes in patients with persistent diabetic macular edema (DME) who switched from ranibizumab to aflibercept with those who continued with previous ranibizumab therapy. Methods.
Ali Demircan, Zeynep Alkin, Ceren Yesilkaya, Gokhan Demir, Burcu Kemer   +4 more
doaj   +1 more source

Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis [PDF]

, 2015
Background: To investigate whether treatment as required ‘pro re nata’ (PRN) versus regular monthly treatment regimens lead to differences in outcomes in neovascular age-related macular degeneration (nAMD).
Agostini, Hansjuergen, Ehlken, Christoph, Loke, Yoon K., Oeller, Patrick, Rücker, Gerta, Schmucker, Christine M., Sommer, Harriet, Virgili, Gianni   +7 more
core   +3 more sources

Lasting Controversy on Ranibizumab and Bevacizumab [PDF]

Theranostics, 2011
Vascular endothelial growth factor (VEGF), an important angiogenic factor that is able to stimulate the proliferation and migration of endothelial cells, is the best-studied hallmark of angiogenesis. Neovascularization is a major cause of age-related macular degeneration (AMD) which is a leading cause of blindness in the elderly population.
Qi Zhou, Huiying Lai, Lihui Zou, Fei Xiao   +3 more
openaire   +3 more sources

Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme [PDF]

, 2014
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Peer reviewedPublisher ...
A D Morris, Cheng, D T Cromie, D W M Pearson, Elman, G P Leese, Ghafour, H C Looker, H M Colhoun, Hammes, J A McKnight, J A Olson, J Doig, Klein, Klein, Klein, Kohner, LeCaire, Leese, Leese, Looker, Looker, M W Black, Misra, Murgatroyd, N Lee, Olson, Pandit, Philip, R S Lindsay, Roy, S H Wild, S O Nyangoma, S Philip, Stratton, van Leiden, Zhang   +36 more
core   +7 more sources

Integrated results from the COPERNICUS and GALILEO studies. [PDF]

, 2017
OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO.
Ahlers, Christiane, Asmus, Friedrich, Boyer, David S., Clark, W. Lloyd, Haller, Julia A., Holz, Frank G., Korobelnik, Jean-Francois, Ogura, Yuichiro, Pielen, Amelie, Rittenhouse, Kay D., Saroj, Namrata, Stemper, Brigitte, Vitti, Robert, Zeitz, Oliver   +13 more
core   +3 more sources

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]

, 2020
AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J, Cheng, Lingyun, Dans, Kunny C, Freeman, William R, Lin, Tiezhu, Meshi, Amit, Muftuoglu, Ilkay Kilic   +6 more
core  

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. [PDF]

, 2018
In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and ...
Antonini, Bodis-Wollner, Brilliant, Brown, Chung, Cutroneo, de Jong, Ding, Drake, Enders, Falk, Gibson, Kemp, Krum, Miners, Naranjo, Nowacka, Nowacka, Piltonen, Pitzer, Poewe, Postuma, Pratt, Quittet, Rosenfeld, Shamloo, Sheikh, Silverman, Slotnick, Stewart, Storkebaum, Tian, Trost, Ueta, Whitton, Wu, Yasuda, Yasuhara, Yasuhara, Yasuhara, Yla-Herttuala, Yue, Zachary, Zehetner   +43 more
core   +2 more sources

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

JAMA ophthalmology, 2020
This phase 2 randomized clinical trial assesses the efficacy and safety of different doses and regimens of faricimab vs ranibizumab in patients with neovascular age-related macular degeneration.
J. Sahni, P. Dugel, Sunil S. Patel, M. Chittum, B. Berger, M. del Valle Rubido, S. Sadikhov, P. Szczęsny, D. Schwab, E. Nogoceke, R. Weikert, S. Fauser   +11 more
semanticscholar   +1 more source

Ranibizumab in retinopathy of prematurity – one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study

Acta ophthalmologica, 2021
The primary endpoint results from the comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity (CARE‐ROP) core study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP).
A. Stahl, Marie-Christine Bründer, W. Lagrèze, Fanni E Molnár, T. Barth, N. Eter, R. Guthoff, T. Krohne, J. Pfeil   +8 more
semanticscholar   +1 more source